Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Archivum Immunologiae Et Therapiae Experimentalis|March 2, 2010
Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic IndexEwa Lech-Maranda, Jacques Bienvenu, Florence Broussais-Guillaumot, et al.
Blood|January 1, 2004
Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphomaEwa Lech-Maranda, Lucile Baseggio, Jacques Bienvenu, et al.
European Journal of Haematology|April 21, 2015
Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patientsPatryk Gorniak, Anna Ejduk, Katarzyna Borg, et al.
Archivum Immunologiae Et Therapiae Experimentalis|January 4, 2013
Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large B-cell lymphomaEwa Lech-Maranda, Jacques Bienvenu, Florence Broussais-Guillaumot, et al.
Cancer|May 13, 2008
Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research GroupEwa Kalinka-Warzocha, Jaroslaw Wajs, Ewa Lech-Maranda, et al.
Blood Advances|June 30, 2018
Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemiaAnthony S Stein, Richard A Larson, Andre C Schuh, et al.
Leukemia & Lymphoma|January 7, 2009
Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemiaJoanna Gora-Tybor, Krzysztof Jamroziak, Anna Szmigielska-Kaplon, et al.
Leukemia & Lymphoma|September 7, 2018
Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational statusEwelina Ziolkowska, Dariusz Wolowiec, Pawel Karpinski, et al.
Blood|September 28, 2002
Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcomePrzemyslaw Juszczynski, Ewa Kalinka, Jacques Bienvenu, et al.
BMC Cancer|July 9, 2015
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)Aleksandra Butrym, Ewa Lech-Maranda, Elżbieta Patkowska, et al.
Pageof 7